Executive Summary
UnitedHealth Group Incorporated (NYSE: UNH) presents a compelling investment opportunity based on its robust long-term growth prospects within the expanding U.S. healthcare market. Despite recent headwinds related to elevated utilization in its Medicare Advantage (MA) business, UNH’s scale, diversified business model through Optum, and proactive cost management initiatives position it for sustained growth. We initiate coverage with a Buy rating and a 12-month price target of $375, representing a 23% upside from the current share price (as of July 27, 2025, Bloomberg: UNH US Equity). This target is derived from a discounted cash flow (DCF) valuation, supported by relative valuation analysis.
Industry Overview
The U.S. healthcare market, estimated at $4.8 trillion in 20251, is projected to reach $8.0 trillion by 2030, driven by an aging population and increasing demand for healthcare services.2 The MA market, a key growth area for UNH, is expected to continue its expansion at a CAGR of 8% through 2030, fueled by the growing number of beneficiaries eligible for Medicare.3 Increased focus on value-based care and technological advancements further shape the industry landscape, creating opportunities for companies like UNH that can leverage data and technology to improve care delivery and manage costs effectively.
Company Analysis
UNH operates through two primary segments: UnitedHealthcare, the largest U.S. health insurer, and Optum, a rapidly growing health services platform. UnitedHealthcare provides health benefits to over 53 million members, covering commercial, Medicare, Medicaid, and individual markets.4 Optum offers a diversified suite of services, including pharmacy benefit management (OptumRx), care delivery (OptumHealth), and data analytics and technology solutions (OptumInsight), serving over 100 million consumers.4 This integrated model allows UNH to effectively manage healthcare costs and improve patient outcomes, driving growth and profitability.
Investment Thesis
Our investment thesis is predicated on UNH’s ability to capitalize on the long-term growth opportunities within the U.S. healthcare market, leveraging its scale, integrated business model, and technology-driven solutions. Key drivers supporting our thesis include:
- Market Leadership and Diversification: UNH’s leading position in health insurance and diversified Optum portfolio provide a resilient revenue base and exposure to multiple growth areas within healthcare.
- Optum Growth Engine: Optum’s rapid expansion, driven by increasing demand for value-based care solutions and technology-enabled services, contributes significantly to UNH’s overall growth and profitability.
- Technology and Data Analytics: UNH’s significant investments in data analytics and technology platforms, coupled with Optum’s comprehensive data assets, enable effective cost management, personalized care delivery, and improved outcomes, creating a competitive advantage.
- Proactive Cost Management: UNH’s aggressive cost management initiatives, including addressing the recent MA utilization challenges, demonstrate its commitment to margin expansion and long-term value creation.
Valuation & Forecasts
We employed a DCF model to determine our price target, incorporating a 3-stage growth approach and a weighted average cost of capital (WACC) of 8.5%. Key assumptions include a revenue CAGR of 9% over the next five years, driven by Optum’s continued expansion and growth in MA membership, and a target operating margin of 15.5% by 2027. Sensitivity analysis reveals that our valuation is most sensitive to changes in long-term growth rates and terminal growth assumptions.
| Year | 2025E | 2026E | 2027E |
|---|---|---|---|
| Revenue ($B) | 302.5 | 330.0 | 360.0 |
| EBITDA ($B) | 45.0 | 51.0 | 57.5 |
| FCF ($B) | 30.0 | 34.0 | 38.5 |
Source: Company filings, author’s estimates
Relative valuation analysis, using a peer group comprising Humana (HUM), CVS Health (CVS), and Elevance Health (ELV), supports our price target. UNH currently trades at a premium to its peers on a P/E basis, reflecting its superior growth prospects and market position. However, we believe this premium is justified given UNH’s stronger long-term growth outlook.
Risks
Key risks to our investment thesis include:
- Medicare Advantage Reimbursement Risk: Changes in government reimbursement rates for MA could materially impact UNH’s profitability.
- Medical Cost Inflation: Sustained high levels of medical cost inflation could pressure margins and impact earnings growth.
- Regulatory Scrutiny: Increased regulatory scrutiny of the healthcare industry, particularly related to pricing and competition, could negatively impact UNH’s operations.
- Competition: Intensifying competition within the health insurance and healthcare services markets could pressure pricing and market share.
- Integration Risks: Potential challenges integrating acquisitions could disrupt operations and impact profitability.
Recommendation
We initiate coverage on UNH with a Buy rating and a 12-month price target of $375. We believe that UNH’s dominant market position, diversified business model, and focus on technology and data analytics position it for sustainable long-term growth. While recent headwinds in the MA business present near-term challenges, we believe that UNH’s proactive cost management initiatives and the long-term growth potential of the MA market outweigh these concerns. We see the current share price as an attractive entry point for long-term investors.
1 Centers for Medicare & Medicaid Services (CMS), National Health Expenditure Data, 2025.
2 CMS, National Health Expenditure Projections, 2025-2030.
3 L.E.K. Consulting, “Medicare Advantage Market Outlook,” 2025.
4 UnitedHealth Group, Q1 2025 Earnings Release.
